5:18 PM ET
10-Q
Financial Results
Pasithea Therapeutics Q3 2026 Results: Net Loss of $6.58M, Loss Widens
Pasithea Therapeutics Corp. reported a net loss of $14.7 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses to $11.1 million. The company maintained a cash position of $41.2 million as of the end of the period, down from $55.2 million at the start of the year.
- Key figure
- Net loss $6.58M